title: Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma.
abstract: Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into phase I clinical trial.
authors: The Brain Tumor Center; The University of Chicago Pritzker School of Medicine; Chicago, IL USA.
authors: Derek A
authors: DA
authors: Wainwright
authors: The Brain Tumor Center; The University of Chicago Pritzker School of Medicine; Chicago, IL USA.
authors: Maciej S
authors: MS
authors: Lesniak
keywords: glioblastoma; immunosuppression; immunotherapy; metabolism; tryptophan